Bank of Montreal’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-37,230
| Closed | -$666K | – | 4057 |
|
|
2021
Q3 | $666K | Sell |
37,230
-207,152
| -85% | -$2.42M | ﹤0.01% | 2714 |
|
|
2021
Q2 | $2.41M | Sell |
244,382
-2,307
| -0.9% | -$21.7K | ﹤0.01% | 1959 |
|
|
2021
Q1 | $2.76M | Buy |
246,689
+78,050
| +46% | +$965K | ﹤0.01% | 1626 |
|
|
2020
Q4 | $2.42M | Buy |
168,639
+14,692
| +10% | +$212K | ﹤0.01% | 1738 |
|
|
2020
Q3 | $2.34M | Buy |
153,947
+149,864
| +3,670% | +$1.49M | ﹤0.01% | 1602 |
|
|
2020
Q2 | $30K | Buy |
+4,083
| New | +$25.3K | ﹤0.01% | 3678 |
|
|
2020
Q1 | – | Sell |
-18,333
| Closed | -$19K | – | 4977 |
|
|
2019
Q4 | $19K | Hold |
18,333
| – | – | ﹤0.01% | 4354 |
|
|
2019
Q3 | $6K | Buy |
+18,333
| New | +$6.2K | ﹤0.01% | 4541 |
|
|
2016
Q4 | – | Sell |
-49
| Closed | -$1K | – | 4250 |
|
|
2016
Q3 | $1K | Sell |
49
-151
| -76% | -$1.74K | ﹤0.01% | 3963 |
|
|
2016
Q2 | $2K | Buy |
+200
| New | +$2.08K | ﹤0.01% | 3921 |
|
|
2015
Q4 | – | Sell |
-44
| Closed | -$1K | – | 4503 |
|
|
2015
Q3 | $1K | Buy |
+44
| New | +$809 | ﹤0.01% | 3912 |
|
Other funds holding TRIL
Bank of Montreal's TRIL Position: Q4 2021 in Review
Bank of Montreal sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 37,230 shares — an estimated $666K sold.
Bank of Montreal first reported a position in TRIL in Q3 2015 and held it in 11 quarters. The position peaked at $2.76M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Bank of Montreal reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Bank of Montreal sold 37,230 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $666K.
- Bank of Montreal first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 11 quarters.
- Bank of Montreal's Trillium Therapeutics Inc. position peaked at $2.76M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Bank of Montreal's 13F filing for Q4 2021, filed 11 Feb 2022.